Key result
Isosorbide mononitrate (20 mg three times daily) markedly reduced angina frequency, completely eliminating attacks in approximately 50% of patients, and improved exercise tolerance.
Why the study?
Does isosorbide mononitrate improve angina frequency and exercise tolerance in patients with angina pectoris?
Does isosorbide mononitrate improve angina frequency and exercise tolerance in patients with angina pectoris?
Answers are grounded in this paper and cite their sources.
Isosorbide mononitrate 20 mg three times daily is well-tolerated and effectively reduces angina frequency and improves exercise tolerance in patients with coronary heart disease.
An open, multi-centre clinical trial was carried out in 537 hospital patients and 2138 general practice patients to evaluate the efficacy and tolerance of isosorbide 5-mononitrate in the treatment of angina pectoris. Prior to entry into the trial, angina attack frequency and acute glyceryl trinitrate consumption were assessed during previous, in most cases unsatisfactory, anti-anginal therapy. After a treatment-free washout period of 3 days, graded multi-stage exercise testing was performed and then treatment started with 20 mg isosorbide mononitrate 3-times per day. Exercise testing was repeated after 14 days' therapy and, in the case of the hospital patients, also 4 to 5 hours after the first dose of isosorbide mononitrate. At the end of the 14-day treatment period, angina attack frequency and glyceryl trinitrate consumption were again assessed. Similar results were obtained for both hospital and general practice patients. Changing to isosorbide mononitrate resulted in a marked reduction in angina frequency, with complete elimination of angina attacks in approximately half of the patients; nocturnal angina, present in approximately 20% of the patients during previous therapy, virtually disappeared during isosorbide mononitrate therapy. Exercise tolerance and performance improved in the majority of patients, with a marked increase in the number of patients able to exercise to the level at which some symptom other than angina pectoris caused them to stop. ST-depression during exercise and exercise-induced arrhythmias also showed clear reductions during isosorbide mononitrate therapy. Tolerance to isosorbide mononitrate was good, the expected 'nitrate headaches' being the only common side-effect reported. The results were such that continuation of treatment with isosorbide mononitrate after the trial was recommended by the attending physician in 77% of the hospital patients and 87% of the general practice patients.
No takes yet. Share an insight, caveat, or question.
Marten et al. (1984) studied angina pectoris (n=2,675). isosorbide mononitrate vs. previous anti-anginal therapy was evaluated on angina attack frequency and glyceryl trinitrate consumption. Isosorbide mononitrate (20 mg three times daily) markedly reduced angina frequency, completely eliminating attacks in approximately 50% of patients, and improved exercise tolerance.
Synapse has enriched 10 related papers. Consider them for comparative context: